Regeneration of Tissues and Organs Using Autologous Cells
The Joint Commission for Health Care Organizations recently declared the shortage of transplantable organs and tissues a public health crisis. As such, there is about one death every 30 seconds due to organ failure. Complications and rejection are still significant albeit underappreciated problems. It is often overlooked that organ transplantation results in the patient being placed on an immune suppression regimen that will ultimate shorten their life span. Patients facing reconstruction often find that surgery is difficult or impossible due to the shortage of healthy autologous tissue. In many cases, autografting is a compromise between the condition and the cure that can result in substantial diminution of quality of life. The national cost of caring for persons who might benefit from engineered tissues or organs has reached $600 billion annually. Autologous tissue technologies have been developed as an alternative to transplantation or reconstructive surgery. Autologous tissues derived from the patient's own cells are capable of correcting numerous pathologies and injuries. The use of autologous cells eliminates the risks of rejection and immunological reactions, drastically reduces the time that patients must wait for lifesaving surgery, and negates the need for autologous tissue harvest, thereby eliminating the associated morbidities. In fact, the use of autologous tissues to create functional organs is one of the most important and groundbreaking steps ever taken in medicine. Although the basic premise of creating tissues in the laboratory has progressed dramatically, only a limited number of tissue developments have reached the patients to date. This is due, in part, to the several major technological challenges that require solutions. To that end, we have been in pursuit of more efficient ways to expand cells in vitro, methods to improve vascular support so that relevant volumes of engineered tissues can be grown, and constructs that can mimic the native tissue environment to ensure tissue integration, maturation, and survival. Other long-term benefits of this research are likely to be cell-based drug delivery mechanisms, intelligent biomaterials, bio-nano technologies, as well as controlled delivery using advances in materials science. The major challenges to the goal of producing tissues and organs for transplantation and reconstruction are three-fold and will form the basis for the goals of this research. These include (1) Identifying sources of autologous cells and developing methods to expand them in large number in vitro, (2) Providing vascular support for growing constructs, and (3) Developing biomaterials and bioreactor systems that mimic the native tissue environment.
- Research Organization:
- Wake Forest University Health Sciences
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- FG02-06ER64240
- OSTI ID:
- 977185
- Report Number(s):
- DOE/ER/64240 Final Report; TRN: US201111%%697
- Country of Publication:
- United States
- Language:
- English
Similar Records
Tumor Engineering: The Other Face of Tissue Engineering
In-111 oxine autologous labeled platelets in the diagnosis of kidney graft rejection